Navigation Links
Raj Khankari Named Bioenergy, Inc., CEO

MINNEAPOLIS, July 16 /PRNewswire/ -- In a statement released today, Bud Hayden, a director serving as interim CEO of Bioenergy, Inc., a privately held Minneapolis-based integrative life science company, announced Raj Khankari, PhD, will join the company as its new CEO on August 1, 2008.


Dr. Khankari joins the company from CIMA Labs Inc., a Cephalon company, where he served as General Manager, CIMA Labs Inc., and Vice President for Worldwide Drug Delivery Technologies. Dr. Khankari earned his initial degrees in Pharmaceutics from universities in India. Dr. Khankari also has a PhD in Pharmaceutics and an MBA from the University of Minnesota.

In addition to holding several patents, Dr. Khankari has been widely published in several peer reviewed journals and has been a presenter at more than two dozen national and international meetings.

In making the announcement, Mr. Hayden stated, "We are very pleased to have Dr. Khankari head up our Company. His scientific background, including his successful track record in working with the Food and Drug Administration (FDA) on new product discoveries, in conjunction with the experience he gained in holding senior management positions, will provide the leadership Bioenergy needs to take advantage of our strong intellectual property portfolio."

In addition to its pharmaceutical subsidiary company, Bioenergy has two other subsidiaries. Bioenergy Life Science, Inc. manufactures and sells D-ribose as an ingredient to nutraceuticals firms marketing beverages and foods, as a medical food through doctors and clinics and as a dietary supplement for energy recovery (reduces fatigue, muscle pain, soreness and stiffness following exercise). Viacell, LLC is engaged in developing technology related to the enhancement of blood components.

D-Ribose is a naturally occurring monosaccharide the body uses to stimulate the synthesis of adenosine triphosphate (ATP), an essential energy compound. ATP is critical to health and maintaining normal energy-dependent body functions. Ribose is an essential component in the cellular production of ATP.

D-Ribose has been shown to increase functional capacity for patients with congestive heart failure (CHF) by improving diastolic heart function, ventilation, exercise capacity, and oxygen uptake efficiency. It's also widely used to help treat Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FMS). D-ribose is commonly found in more and more functional foods like energy bars (e.g., Detour, FastFuel, Marathon) and drinks (e.g., Vitamin Water, SoBe Life Water, Snapple Antioxidant Water).

Bioenergy, Inc. ( is a privately held, Minneapolis-based life sciences company whose core technology lies in the development and commercialization of products based on the physiological benefits of D-ribose in health and wellness.

SOURCE Bioenergy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Samarion CEO Mark Rodgers Named CAST Commissioner
2. North Carolina Marketing Firm MicroMass Named One of Top 60 Healthcare Agencies in U.S.
3. Quintiles Named to Computerworld Magazines 100 Best Places to Work in Information Technology List
4. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
5. Agensys Founder, President, & CEO Dr. Donald Rice Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Winner for the Greater Los Angeles Area
6. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
7. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
8. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
9. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
10. Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association
11. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
Post Your Comments:
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
Breaking Biology News(10 mins):